Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:32 pm Purchase | 2024-09-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB | Paradigm BioCapital Advisors LP | 4,086,346 9.200% | 1,888,034 (+85.89%) | Filing History |
| 2024-11-14 4:31 pm Purchase | 2024-09-30 | 13G | Kura Oncology, Inc. KURA | Paradigm BioCapital Advisors LP | 4,331,321 5.700% | 470,003 (+12.17%) | Filing History |
| 2024-10-23 5:39 pm Purchase | 2024-10-16 | 13G | Janux Therapeutics, Inc. JANX | Paradigm BioCapital Advisors LP | 2,608,574 5.000% | 2,608,574 (New Position) | Filing History |
| 2024-10-04 5:34 pm Purchase | 2024-09-24 | 13G | Pliant Therapeutics, Inc. PLRX | Paradigm BioCapital Advisors LP | 3,059,411 5.030% | 3,059,411 (New Position) | Filing History |
| 2024-05-02 4:34 pm Purchase | 2024-04-22 | 13G | Kura Oncology, Inc. KURA | Paradigm BioCapital Advisors LP | 3,861,318 5.100% | 3,861,318 (New Position) | Filing History |
| 2024-04-08 5:09 pm Purchase | 2024-03-27 | 13G | Y-mAbs Therapeutics, Inc. YMAB | Paradigm BioCapital Advisors LP | 2,198,312 5.020% | 2,198,312 (New Position) | Filing History |
| 2024-02-14 5:57 pm Purchase | 2023-12-31 | 13G | Arcellx, Inc. ACLX | Paradigm BioCapital Advisors LP | 3,658,624 7.000% | 1,235,924 (+51.01%) | Filing History |
| 2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Ambrx Biopharma Inc. AMAM | Paradigm BioCapital Advisors LP | 4,502,689 7.100% | 4,502,689 (New Position) | Filing History |
| 2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN | Paradigm BioCapital Advisors LP | 3,176,743 5.500% | 859,109 (+37.07%) | Filing History |
| 2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Autolus Therapeutics plc AUTL | Paradigm BioCapital Advisors LP | 12,611,335 7.200% | 2,512,751 (+24.88%) | Filing History |
| 2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Bicycle Therapeutics plc BCYC | Paradigm BioCapital Advisors LP | 3,707,001 9.800% | 2,096,336 (+130.15%) | Filing History |
| 2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Disc Medicine, Inc. IRON | Paradigm BioCapital Advisors LP | 2,385,857 9.900% | 1,149,939 (+93.04%) | Filing History |
| 2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Paradigm BioCapital Advisors LP | 5,304,313 9.990% | 2,993,615 (+129.55%) | Filing History |
| 2024-02-14 4:08 pm Sale | 2023-12-31 | 13G | Vor Biopharma Inc. VOR | Paradigm BioCapital Advisors LP | 6,457,293 9.500% | -20,706 (-0.32%) | Filing History |
| 2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Nuvalent, Inc. NUVL | Paradigm BioCapital Advisors LP | 3,858,008 6.700% | 478,928 (+14.17%) | Filing History |
| 2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Olema Pharmaceuticals, Inc. OLMA | Paradigm BioCapital Advisors LP | 7,903,600 14.300% | 100,000 (+1.28%) | Filing History |
| 2024-02-14 4:08 pm Unchanged | 2023-12-31 | 13G | COMPASS Pathways plc CMPS | Paradigm BioCapital Advisors LP | 3,425,988 5.400% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:08 pm Sale | 2024-01-26 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP | Paradigm BioCapital Advisors LP | 0 0.000% | -399,658 (Position Closed) | Filing History |
| 2024-02-05 4:21 pm Purchase | 2024-01-26 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP | Paradigm BioCapital Advisors LP | 399,658 9.000% | 399,658 (New Position) | Filing History |
| 2024-01-22 5:05 pm Purchase | 2024-01-12 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Paradigm BioCapital Advisors LP | 1,927,506 5.800% | 1,927,506 (New Position) | Filing History |